It has other candidates in its late-stage obesity pipeline, headed by CagriSema, which combines dual amylin and calcitonin receptor agonist cagrilintide with semaglutide. Phase 3 results reported ...
a once-weekly injectable combination of semaglutide and amylin analogue cagrilintide that should have late-stage data early next year. The early-stage data shows that the company has compounds ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback